MA46708A - Anticorps anti-pd1 et leurs utilisations - Google Patents

Anticorps anti-pd1 et leurs utilisations

Info

Publication number
MA46708A
MA46708A MA046708A MA46708A MA46708A MA 46708 A MA46708 A MA 46708A MA 046708 A MA046708 A MA 046708A MA 46708 A MA46708 A MA 46708A MA 46708 A MA46708 A MA 46708A
Authority
MA
Morocco
Prior art keywords
antibodies
Prior art date
Application number
MA046708A
Other languages
English (en)
Other versions
MA46708B1 (fr
Inventor
George Robert Mabry Iii
Stephen Sazinsky
Original Assignee
Jounce Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jounce Therapeutics Inc filed Critical Jounce Therapeutics Inc
Publication of MA46708A publication Critical patent/MA46708A/fr
Publication of MA46708B1 publication Critical patent/MA46708B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA46708A 2016-11-02 2017-11-01 Anticorps anti-pd1 et leurs utilisations MA46708B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416602P 2016-11-02 2016-11-02
PCT/US2017/059481 WO2018085358A1 (fr) 2016-11-02 2017-11-01 Anticorps dirigés contre pd-1 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA46708A true MA46708A (fr) 2021-05-05
MA46708B1 MA46708B1 (fr) 2021-10-29

Family

ID=60543661

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46708A MA46708B1 (fr) 2016-11-02 2017-11-01 Anticorps anti-pd1 et leurs utilisations

Country Status (30)

Country Link
US (3) US10654929B2 (fr)
EP (2) EP3988569A1 (fr)
JP (2) JP7086066B2 (fr)
KR (1) KR20190088480A (fr)
CN (1) CN110392694B (fr)
AR (1) AR110017A1 (fr)
AU (1) AU2017355401A1 (fr)
BR (1) BR112019008494A2 (fr)
CA (1) CA3039992A1 (fr)
CY (1) CY1124730T1 (fr)
DK (1) DK3535298T3 (fr)
ES (1) ES2898025T3 (fr)
HR (1) HRP20211703T1 (fr)
HU (1) HUE057559T2 (fr)
IL (1) IL266259A (fr)
LT (1) LT3535298T (fr)
MA (1) MA46708B1 (fr)
MD (1) MD3535298T2 (fr)
MX (1) MX2019004834A (fr)
MY (1) MY195110A (fr)
PL (1) PL3535298T3 (fr)
PT (1) PT3535298T (fr)
RS (1) RS62589B1 (fr)
RU (1) RU2761640C2 (fr)
SG (1) SG11201903857UA (fr)
SI (1) SI3535298T1 (fr)
SM (1) SMT202100650T1 (fr)
TW (2) TWI781120B (fr)
WO (1) WO2018085358A1 (fr)
ZA (1) ZA201902455B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3313883B1 (fr) * 2015-06-23 2023-12-06 Memorial Sloan Kettering Cancer Center Nouveaux agents de modulation immunitaire pd -1
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3497128A2 (fr) 2016-08-09 2019-06-19 Kymab Limited Anticorps anti-icos
HRP20211703T1 (hr) 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
WO2018127918A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion sirp alpha-cd70 et ses procédés d'utilisation
WO2018127916A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion pd1-cd70 et ses procédés d'utilisation
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
ES2910969T3 (es) 2017-08-03 2022-05-17 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
EP3728314A1 (fr) 2017-12-19 2020-10-28 Kymab Limited Anticorps bispécifique pour icos et pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
SG11202013170RA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
KR20210044220A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
US11564995B2 (en) * 2018-10-29 2023-01-31 Wisconsin Alumni Research Foundation Peptide-nanoparticle conjugates
EP3998081A4 (fr) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. Traitement du cancer hématologique avec une protéine à double spécificité pd-1/cd3
JP7771749B2 (ja) 2019-08-08 2025-11-18 小野薬品工業株式会社 二重特異性タンパク質
CN110669108A (zh) * 2019-09-06 2020-01-10 中国药科大学 一种多肽及其应用
CN110590959B (zh) * 2019-09-19 2021-01-05 北京伟杰信生物科技有限公司 重组犬pd-1融合蛋白及其制备方法与应用
US20220378909A1 (en) * 2019-11-05 2022-12-01 Jounce Therapeutics, Inc. Methods of Treating Cancer with Anti-PD-1 Antibodies
CN110964111B (zh) * 2019-12-25 2020-07-24 北京东方百泰生物科技有限公司 一种抗pd-l1单克隆抗体、其抗原结合片段及其应用
CN111175489B (zh) * 2020-01-03 2021-03-30 山西大学 磁珠评价免疫检查点分子阻断性抗体阻断活性方法
US20230069055A1 (en) * 2020-01-21 2023-03-02 Bolt Biotherapeutics, Inc Anti-pd-l1 antibodies
MX2022008925A (es) * 2020-01-21 2022-10-18 Bolt Biotherapeutics Inc Anticuerpos anti-pd-l1.
IL295023A (en) * 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and their uses
PH12022553181A1 (en) 2020-05-26 2024-03-04 Boehringer Ingelheim Int Anti-pd-1 antibodies
IL299238A (en) * 2020-06-23 2023-02-01 Kadmon Corp Llc ANTI-PD-1 antibodies and fusion proteins
AU2021330087B2 (en) * 2020-08-31 2025-10-23 Biosion Inc. PD-1 binding antibodies and uses thereof
CN114316022A (zh) * 2020-09-30 2022-04-12 正大天晴康方(上海)生物医药科技有限公司 结合pd-1抗体的肽及其应用
KR102661163B1 (ko) * 2021-02-04 2024-04-26 주식회사 지뉴브 항 pd-1 항체 및 그의 용도
US20240141014A1 (en) * 2021-03-03 2024-05-02 Shattuck Labs, Inc. Mutant pd-1 extracellular domains
US12491176B2 (en) 2021-04-21 2025-12-09 The Trustees Of Columbia University In The City Of New York Methods, compositions, kits and uses thereof targeting and/or treating VRK2 to enhance effectiveness of immune checkpoint inhibitor(s)
KR102450914B1 (ko) 2022-03-23 2022-10-06 재단법인 경북아이티융합 산업기술원 차량 간 통신 기반 차량 무선 업데이트 방법 및 시스템
CN120225558A (zh) * 2022-10-05 2025-06-27 朱拉隆功大学 针对人程序性细胞死亡蛋白1(pd-1)的单克隆抗体
CN116854820B (zh) * 2023-06-26 2024-02-06 华中科技大学同济医学院附属协和医院 Pd-1非阻断性清除抗体及其用途
CN117756915B (zh) * 2023-11-24 2025-05-30 河南省肿瘤医院 一组阻断抗pd-1抗体与细胞表面pd-1分子结合的pd-1分子及其突变体和用途
KR20250087149A (ko) 2023-12-07 2025-06-16 재단법인 경북아이티융합 산업기술원 차량용 무선 업데이트 검사 절차, 관리 시스템 및 동작 방법

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1028751B1 (fr) 1997-10-31 2008-12-31 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (fr) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
WO2001044463A1 (fr) 1999-12-15 2001-06-21 Genentech, Inc. Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
EP2206517B1 (fr) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes contenant un anticorps anti-PD-L1
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
CN101979650B (zh) 2003-10-22 2015-09-16 凯克研究生院 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (fr) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition a base d'anticorps
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2589895A1 (fr) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Sequences de tete de conduite de la secretion de polypeptides et methodes de production associees
ES2720160T3 (es) * 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
EP1973951A2 (fr) 2005-12-02 2008-10-01 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
WO2007134050A2 (fr) 2006-05-09 2007-11-22 Genentech, Inc. Polypeptides de liaison à squelettes optimisés
EA018030B1 (ru) 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN101679966B (zh) 2007-01-24 2014-03-12 协和发酵麒麟株式会社 具有增强的效应子活性的遗传重组抗体组合物
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ， エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
US9783578B2 (en) * 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR102810907B1 (ko) 2010-07-16 2025-05-21 아디맵 엘엘씨 항체 라이브러리
WO2013149219A2 (fr) 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Anticorps complètement humains qui se lient à vegfr2
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
EP2911669B1 (fr) 2012-10-26 2024-04-10 The University of Chicago Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
US20150368316A1 (en) * 2013-02-07 2015-12-24 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
KR20250091304A (ko) 2013-03-15 2025-06-20 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
MA38483A1 (fr) 2013-03-15 2018-02-28 Bristol Myers Squibb Co Inhibiteurs de l'ido
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
ES2746805T3 (es) * 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
EP3142690B1 (fr) * 2014-05-13 2022-02-23 Bavarian Nordic A/S Polythérapie destinée à traiter le cancer avec un poxvirus recombinant exprimant un antigène tumoral et un antagoniste ou agoniste d'une molécule inhibitrice de points de contrôle immunitaires
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9982053B2 (en) * 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
HRP20201153T1 (hr) 2014-08-08 2021-01-22 The Board Of Trustees Of The Leland Stanford Junior University Pd-1 sredstva visokog afiniteta i načini uporabe
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
CA3175979A1 (fr) * 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anticorps anti-pd-1
SG10201912943RA (en) * 2015-10-02 2020-02-27 Symphogen As Anti-pd-1 antibodies and compositions
CN105153315B (zh) * 2015-10-09 2019-04-02 重庆精准生物技术有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
US10294299B2 (en) 2016-01-22 2019-05-21 MabQuest SA Immunological reagents
CN105601752B (zh) * 2016-02-01 2019-08-23 海门郝怡雅医药科技有限公司 一种多基因重组嵌合抗原受体分子
LT3515938T (lt) 2016-09-21 2025-05-12 Cstone Pharmaceuticals Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1)
HRP20211703T1 (hr) 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
JP7110369B2 (ja) 2018-02-23 2022-08-01 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド 抗ｐｄ－１抗体及びその用途

Also Published As

Publication number Publication date
JP7086066B2 (ja) 2022-06-17
HRP20211703T1 (hr) 2022-02-04
DK3535298T3 (da) 2021-11-15
PT3535298T (pt) 2021-11-25
JP2019534008A (ja) 2019-11-28
AR110017A1 (es) 2019-02-13
RS62589B1 (sr) 2021-12-31
US20180118829A1 (en) 2018-05-03
JP2022070873A (ja) 2022-05-13
SG11201903857UA (en) 2019-05-30
SI3535298T1 (sl) 2022-01-31
MA46708B1 (fr) 2021-10-29
MD3535298T2 (ro) 2022-01-31
CA3039992A1 (fr) 2018-05-11
WO2018085358A1 (fr) 2018-05-11
TW201819411A (zh) 2018-06-01
CN110392694A (zh) 2019-10-29
LT3535298T (lt) 2021-12-27
PL3535298T3 (pl) 2021-12-27
IL266259A (en) 2019-06-30
KR20190088480A (ko) 2019-07-26
US11384147B2 (en) 2022-07-12
MX2019004834A (es) 2019-06-20
HUE057559T2 (hu) 2022-06-28
BR112019008494A2 (pt) 2019-07-09
US20200399374A1 (en) 2020-12-24
EP3535298B1 (fr) 2021-09-08
US20230018445A1 (en) 2023-01-19
ZA201902455B (en) 2020-11-25
AU2017355401A1 (en) 2019-05-02
RU2761640C2 (ru) 2021-12-13
ES2898025T3 (es) 2022-03-03
RU2019116653A (ru) 2020-12-03
EP3535298A1 (fr) 2019-09-11
CY1124730T1 (el) 2022-07-22
MY195110A (en) 2023-01-10
EP3988569A1 (fr) 2022-04-27
US10654929B2 (en) 2020-05-19
CN110392694B (zh) 2023-08-04
US11905329B2 (en) 2024-02-20
RU2019116653A3 (fr) 2021-04-30
SMT202100650T1 (it) 2022-01-10
TW202321301A (zh) 2023-06-01
TWI781120B (zh) 2022-10-21

Similar Documents

Publication Publication Date Title
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3733702A4 (fr) Anticorps anti-lag-3 et utilisations associées
EP3325010A4 (fr) Anticorps anti-facteur de coagulation xia et leurs utilisations